Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC

SOUTH SAN FRANCISCO, CA, Nov 12 (MARKET WIRE) --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that abstracts
summarizing non-clinical data relating to GSK-923295, an inhibitor of
centromere-associated protein E (CENP-E), are scheduled to be presented
at the AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics to be held from November 15-19, 2009 at the Hynes
Convention Center in Boston, Massachusetts.

The presentations contain preclinical data relating to GSK-923295,
currently being studied in a GlaxoSmithKline sponsored Phase I, first time
in humans clinical trial designed to evaluate the safety, tolerability,
pharmacodynamics and pharmacokinetic profile of this novel drug candidate
in patients with solid tumors.

Poster Presentations at AACR-NCI-EORTC Symposium:

Poster #B173: "Synergistic Interaction Between CENP-E inhibitor GSK923295
and MEKi Inhibitor GSK1120212," is scheduled to be displayed on Tuesday,
November 17 from 12:30 PM - 2:30 PM Eastern Time in Halls C-D at the
Poster Session B: New Molecular Targets 1. The poster will be presented
by the author, Yan Y. Degenhardt, Ph.D., Manager, Cancer Metabolism,
Oncology R&D, GlaxoSmithKline.

Poster #PR-10 "RNAi-directed
Identification of Chemosensitizers of GSK923295 Response," is scheduled
to be displayed on Wednesday, November 18 from 12:30 PM - 2:30 PM Eastern
Time in Poster Session C: Pharmacogenetics, Pharmacogenomics, and
Therapeutic Response in Halls C-D. The poster will be presented by the
author, Holly Yin, Ph.D., Head of Cellular Genomics, Translational
Genomics Research Institute (TGen).

Oral Presentation at AACR-NCI-EORTC Symposium:

"RNAi-directed Identification of Chemosensitizers of GSK923295 Response,"
is scheduled to be presented as part of the Proffered Paper Session on
Wednesday, November 18 from 4:30 - 5:30 PM Eastern Time. The presentation
will be made by Holly Yin, Ph.D., Head of Cellular Genomics, Translational
Genomics Research Institute (TGen).

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and
medical conditions. Cytokinetics' lead drug candidate from its cardiac
muscle contractility program, omecamtiv mecarbil (formerly CK-1827452),
is in Phase II clinical development for the potential treatment of heart
failure. Amgen Inc. holds an exclusive license worldwide (excluding
Japan) to develop and commercialize omecamtiv mecarbil and related
compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
developing CK-2017357, a skeletal muscle activator, as a potential
treatment for diseases and conditions associated with aging, muscle
wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical
development. Cytokinetics is also conducting non-clinical development of
compounds that inhibit smooth muscle contractility and which may be
useful as potential treatments for diseases and conditions such as
systemic hypertension, pulmonary arterial hypertension or
bronchoconstriction. In addition, prior Cytokinetics' research generated
three anti-cancer drug candidates in Phase I clinical development:
ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner
for ispinesib and SB-743921 and GSK-923295 is being developed under
Cytokinetics' collaboration with GlaxoSmithKline. All of these drug
candidates and potential drug candidates have arisen from Cytokinetics'
research activities and are directed towards the cytoskeleton. The
cytoskeleton is a complex biological infrastructure that plays a
fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to planned presentations and the
properties and potential benefits of Cytokinetics' drug candidates and
potential drug candidates. Such statements are based on management's
current expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory approval
and production of Cytokinetics' drug candidates and potential drug
candidates that could slow or prevent clinical development or product
approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical
trials results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and other
risks related to Cytokinetics' business, investors should consult
Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Cytokinetics, Incorporated
Christopher S. Keenan (Investors and Media)
Director, Investor Relations
(650) 624-3000

Copyright 2009, Market Wire, All rights reserved.

-0-